Der Internist

, Volume 52, Issue 6, pp 688–696 | Cite as

Behandlung der Komorbiditäten entzündlich-rheumatischer Erkrankungen

Schwerpunkt

Zusammenfassung

Patienten mit entzündlich-rheumatischen Erkrankungen leiden häufig an relevanten Komorbiditäten, die durch die chronisch-entzündliche Systemaktivität der rheumatischen Krankheit selbst, durch Störungen der immunologischen Abwehr oder durch Folgen der antirheumatischen Therapie bedingt sein können, aber auch unabhängig davon auftreten können. So weisen zum Beispiel Patienten mit rheumatoider Arthritis bereits zum Zeitpunkt der Erstmanifestation in knapp 50% der Fälle 2 weitere chronische Krankheiten auf. Hinsichtlich der bei Rheumapatienten erhöhten Mortalität sind v. a. die kardiovaskuläre Morbidität und die erhöhte Disposition für Infektionen zu nennen. In diesem Artikel sollen zudem weitere wichtige mögliche Begleiterkrankungen, nämlich die Osteoporose und Tumorerkrankungen, behandelt werden. Es gilt, Komorbiditäten zu erkennen und ebenso konsequent zu behandeln wie die rheumatische Grunderkrankung, somit den an Rheuma erkrankten Patienten in jeder Krankheitsphase interdisziplinär internistisch zu begleiten. Eine effektive Beherrschung der systemischen Entzündungsaktivität vermag das Risiko bestimmter kardiovaskulärer und neoplastischer Komorbiditäten zu reduzieren.

Schlüsselwörter

Entzündliche Autoimmunerkrankung Kardiovaskuläre Komorbidität Neoplastische Komorbidität Osteoporose Infektion 

Managing comorbidities of inflammatory rheumatic diseases

Abstract

Patients with inflammatory rheumatic diseases often suffer from considerable comorbidities that can arise due to the chronic systemic inflammatory activity of the rheumatic disease itself, disorders of immune defense, or as a result of antirheumatic treatment; they can also occur independently. For example, almost 50% of patients with rheumatoid arthritis already exhibit two further chronic diseases at the time of initial manifestation. With regard to the elevated mortality observed in patients with rheumatism, particularly cardiovascular morbidity and increased predisposition to infections are of note. In addition, this article addresses further important possible concomitant diseases, i.e., osteoporosis and tumor diseases. A ground rule is to identify comorbidities and treat them just as diligently as the underlying rheumatic disease so that the patient with rheumatism should be accompanied by an interdisciplinary team of internists during each phase of the disease. Effective control of the systemic inflammatory activity may serve to reduce the risk of certain cardiovascular and neoplastic comorbidities.

Keywords

Inflammatory autoimmune disease Cardiovascular comorbidity Neoplastic comorbidity Osteoporosis Infection 

Literatur

  1. 1.
    Atzeni F, Turiel M, Caporali R et al (2010) The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 9:835–839PubMedCrossRefGoogle Scholar
  2. 2.
    Atzeni F, Turiel M, Hollan I et al (2010) Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 9:845–848PubMedCrossRefGoogle Scholar
  3. 3.
    Baecklund E, Askling J, Rosenquist R et al (2004) Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16:254–261PubMedCrossRefGoogle Scholar
  4. 4.
    Bernatsky S, Ramsey-Goldman R, Rajan R et al (2005) Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507–1509PubMedCrossRefGoogle Scholar
  5. 5.
    Bernatsky SR, Cooper GS, Mill C et al (2006) Cancer screening in patients with systemic lupus erythematosus. J Rheumatol 33:45–49PubMedGoogle Scholar
  6. 6.
    Bertsias G, Ioannidis JP, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 67:195–205PubMedCrossRefGoogle Scholar
  7. 7.
    Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784PubMedCrossRefGoogle Scholar
  8. 8.
    Booth AD, Jayne DR, Kharbanda RK et al (2004) Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109:1718–1723PubMedCrossRefGoogle Scholar
  9. 9.
    Braun J, Pfeilschifter J (2010) Osteoporosis diagnosis and therapy according to the 2010 guidelines. Z Rheumatol 69:327–339PubMedCrossRefGoogle Scholar
  10. 10.
    British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800–805CrossRefGoogle Scholar
  11. 11.
    Carroll MB, Forgione MA (2010) Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 29:1021–1029PubMedCrossRefGoogle Scholar
  12. 12.
    Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308Google Scholar
  13. 13.
    Choi HK, Hernan MA, Seeger JD et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRefGoogle Scholar
  14. 14.
    Culleton BF, Larson MG, Wilson PW et al (1999) Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214–2219PubMedCrossRefGoogle Scholar
  15. 15.
    Dachverband Osteologie (2006) Prophylaxe, Diagnostik und Therapie der Glukokortikoid-induzierten Osteoporose. Langfassung. www.dv-osteologie.orgGoogle Scholar
  16. 16.
    Dachverband Osteologie (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 18:304–328Google Scholar
  17. 17.
    Dixon WG, Symmons DP (2007) What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 66:1132–1136PubMedCrossRefGoogle Scholar
  18. 18.
    Falagas ME, Manta KG, Betsi GI et al (2007) Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 26:663–670PubMedCrossRefGoogle Scholar
  19. 19.
    Faurschou M, Mellemkjaer L, Sorensen IJ et al (2009) Cancer preceding Wegener’s granulomatosis: a case-control study. Rheumatology (Oxford) 48:421–424Google Scholar
  20. 20.
    Faurschou M, Mellemkjaer L, Sorensen IJ et al (2009) Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 60:1187–1192PubMedCrossRefGoogle Scholar
  21. 21.
    Faurschou M, Sorensen IJ, Mellemkjaer L et al (2008) Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:100–105PubMedGoogle Scholar
  22. 22.
    Filer AD, Gardner-Medwin JM, Thambyrajah J et al (2003) Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 62:162–167PubMedCrossRefGoogle Scholar
  23. 23.
    Fischer-Betz R, Halle M, Schneider M (2010) Inflammation-related cardiovascular morbidity: Pathophysiology and therapy. Z Rheumatol 69:680–684, 686–688PubMedCrossRefGoogle Scholar
  24. 24.
    Gerli R, Vaudo G, Bocci EB et al (2010) Functional impairment of the arterial wall in primary Sjogren’s syndrome: combined action of immunologic and inflammatory factors. Arthritis Care Res (Hoboken) 62:712–718CrossRefGoogle Scholar
  25. 25.
    Guillevin L, Cordier JF, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–2198PubMedCrossRefGoogle Scholar
  26. 26.
    Harper L, Savage CO (2005) ANCA-associated renal vasculitis at the end of the twentieth century–a disease of older patients. Rheumatology (Oxford) 44:495–501Google Scholar
  27. 27.
    Hellmich B, Schnabel A, Gross WL (1999) Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener’s granulomatosis. Arthritis Rheum 42:1752–1756PubMedCrossRefGoogle Scholar
  28. 28.
    Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMedGoogle Scholar
  29. 29.
    Holle JU, Gross WL, Latza U et al (2010) Improved outcome of 445 Wegener’s granulomatosis patients in a German vasculitis center over four decades. Arthritis Rheum 63:257–266CrossRefGoogle Scholar
  30. 30.
    Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899PubMedCrossRefGoogle Scholar
  31. 31.
    Kerekes G, Szekanecz Z, Der H et al (2008) Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 35:398–406PubMedGoogle Scholar
  32. 32.
    Lange U, Muller-Ladner U (2007) Glucocorticoid induced osteoporosis. Z Rheumatol 66:129–136PubMedCrossRefGoogle Scholar
  33. 33.
    Lee MS, Smith SD, Galor A et al (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54:3306–3309PubMedCrossRefGoogle Scholar
  34. 34.
    Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54:2129–2138PubMedCrossRefGoogle Scholar
  35. 35.
    Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043PubMedCrossRefGoogle Scholar
  36. 36.
    Mann JF, Gerstein HC, Pogue J et al (2002) Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2:157–162PubMedCrossRefGoogle Scholar
  37. 37.
    Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415PubMedGoogle Scholar
  38. 38.
    Masaki Y, Sugai S (2004) Lymphoproliferative disorders in Sjogren’s syndrome. Autoimmun Rev 3:175–182PubMedCrossRefGoogle Scholar
  39. 39.
    McCarey DW, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRefGoogle Scholar
  40. 40.
    Meyer-Olson D, Hoeper K, Schmidt RE (2010) Infectious complications of biologic therapy in patients with rheumatoid arthritis. Z Rheumatol 69:879–888PubMedCrossRefGoogle Scholar
  41. 41.
    Morgan MD, Turnbull J, Selamet U et al (2009) Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 60:3493–3500PubMedCrossRefGoogle Scholar
  42. 42.
    Niitsu N, Hagiwara Y, Tanae K et al (2010) Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 28:5097–5100PubMedCrossRefGoogle Scholar
  43. 43.
    Palinski W, Tsimikas S (2002) Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 13:1673–1681PubMedCrossRefGoogle Scholar
  44. 44.
    Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331PubMedCrossRefGoogle Scholar
  45. 45.
    Peters MJ, Visman I, Nielen MM et al (2010) Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 69:579–581PubMedCrossRefGoogle Scholar
  46. 46.
    Petri MA, Kiani AN, Post W et al (2011) Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 70:760–765PubMedCrossRefGoogle Scholar
  47. 47.
    Pincus T, Callahan LF, Sale WG et al (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864–872PubMedCrossRefGoogle Scholar
  48. 48.
    Ray JG, Mamdani MM,Geerts WH (2005) Giant cell arteritis and cardiovascular disease in older adults. Heart 91:324–328PubMedCrossRefGoogle Scholar
  49. 49.
    Reinhold-Keller E, Beuge N, Latza U et al (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43:1021–1032PubMedCrossRefGoogle Scholar
  50. 50.
    Ridker PM, Hennekens CH, Buring JE et al (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843PubMedCrossRefGoogle Scholar
  51. 51.
    Rizzi R, Curci P, Delia M et al (2009) Spontaneous remission of „methotrexate-associated lymphoproliferative disorders“ after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26:1–9PubMedCrossRefGoogle Scholar
  52. 52.
    Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I et al (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11:R109PubMedCrossRefGoogle Scholar
  53. 53.
    Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28PubMedCrossRefGoogle Scholar
  54. 54.
    Ruyssen-Witrand A, Fautrel B, Saraux A et al (2010) Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine 77:246–251PubMedCrossRefGoogle Scholar
  55. 55.
    Smitten AL, Choi HK, Hochberg MC et al (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387–393PubMedGoogle Scholar
  56. 56.
    Solomon DH, Curhan GC, Rimm EB et al (2004) Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 50:3444–3449PubMedCrossRefGoogle Scholar
  57. 57.
    Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5PubMedCrossRefGoogle Scholar
  58. 58.
    Tatsis E, Reinhold-Keller E, Steindorf K et al (1999) Wegener’s granulomatosis associated with renal cell carcinoma. Arthritis Rheum 42:751–756PubMedCrossRefGoogle Scholar
  59. 59.
    Tervaert JW (2009) Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 156:377–385PubMedCrossRefGoogle Scholar
  60. 60.
    Thomas CF, Limper AH (2004) Pneumocystis pneumonia. N Engl J Med 350:2487–2498PubMedCrossRefGoogle Scholar
  61. 61.
    van Staa TP, Geusens P, Bijlsma JW et al (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112CrossRefGoogle Scholar
  62. 62.
    Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352:351–361CrossRefGoogle Scholar
  63. 63.
    Westhoff G, Weber C, Zink A (2006) Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters. Z Rheumatol 65:487–488, 490–4, 496PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Medizinische Klinik IIIKlinikum Offenbach GmbHOffenbachDeutschland
  2. 2.Klinik Innere Medizin IVHSK Dr. Horst Schmidt Kliniken GmbHWiesbadenDeutschland

Personalised recommendations